Insight
5 Minutes With Dr James Harmsworth King
From Frontline Medicine to Transforming HealthTech at Scale
In this edition of 5 Minutes With, we speak to Dr James Harmsworth King, a former doctor, researcher and HealthTech founder who has dedicated his career to improving healthcare outcomes at scale. From experiencing the challenges of frontline medicine to building some of the UK’s fastest-growing HealthTech companies, James shares his insights on innovation, leadership and the real-world impact of AI in healthcare.
Chris: You’ve been a doctor, researcher, health tech founder, what’s the common thread that drives your career choices?
James: I’ve always been motivated by delivering the best health outcomes for the most people. Clinical practice has been hugely rewarding but the scale of impact was limited as I could only ever see one patient at a time. Then as a researcher, i was able to experiment with emergent deep learning architectures that one day could change practice far beyond my own clinical impact. Through this clinical and research perspective, I saw how we could use leading edge technology, such as transformer models, as well as repurposing basic digital tools, already prevalent in banking and retail, to facilitate better more efficient healthcare systems. By starting health tech companies I was able apply these discoveries to build scalable healthcare solutions to improve outcomes for thousands and now millions of patients.
Chris: What inspired you to leave frontline medicine to start building HealthTech companies?
James: When I was practicing frontline medicine I experienced first hand the challenges patients and providers face every day, with fragmented, inefficient care, often leading to sub optimal outcomes. I realised that the technology I was exposed to could help solve this with joined up healthcare delivering better patient experience and outcomes. I was already using mathematical modelling for simulating cardiac ion flows to prevent arrhythmias so it was a simple step to apply similar models for clinical workflow to optimise outcomes and deliver efficient healthcare systems.
Chris: You’ve helped scale health tech start ups to become some of the fastest growing companies in the country, what’s the hardest leadership lesson you learned in that journey?
James: Be ready to fail fast and be open to the fact that the most elegant ideas may not practically work or have the most commercial traction. HealthTech has potential to evolve very quickly and many start ups fail to catch up with consumer expectations on convenience, speed and flexibility. The winners tend to move and adapt quickly delivering high-quality user led product. Often the best ideas are leapfrogged if delivered too slowly. The key challenge is to take ideas, both simple and cutting edge, and rapidly shape into a product where patients and physicians sense immediate value.
Chris: For SMEs in HealthTech, when is the “right time” to invest in senior leadership talent?
James: Earlier than you think. Many founders wait until they feel stretched to breaking point, but by then, you’re already limiting growth. The right time is when you have a clear product-market fit and a repeatable commercial model. At that point, investing in senior leadership isn’t a luxury. I would say it’s essential to scale responsibly, attract investment, and avoid founder burnout.
Chris: You’ve worked on AI and data-enabled healthcare products now for over ten years, what excites you most about current AI in HealthTech?
James: The public’s understanding and growing trust of AI, particularly around GPTs has been a step change. Historically these kind of technologies were kept behind the brand – few people knew how Google translate worked – just that it was an excellent product. OpenAI changed that in 2022 when they branded their product with their technology, ChatGPT. For decades there has been recognition of the untapped value of electronic health related data. However few have been able to harness this ballooning amount of data to demonstrate real world clinical value. Now with the pace of LLM and agenic AI development we are beginning to unlock that potential to deliver truly personalised healthcare via interoperable systems.
Chris: There is a huge amount of industry excitement currently around AI, what do you think is overhyped?
James: I speak to a lot of health tech startups who passionately believe GenAI is the product that will single handily “fix” healthcare. AI tools, including GenAI, should only be just one of many technologies selected on merit to build user focused product. If used right, generative AI has the potential to dramatically improve performance for specific, not global tasks, within clinical workflow. It’s essential that companies understand the costs and clinical/ regulatory risks of deploying these often complex tools when a simpler, more mature digital technology may be sufficient. Winners will be able to effectively navigate this balance in spite of the growing hype.
Chris: What do HealthTech founders often underestimate when it comes to working with the NHS?
James: NHS leaders typically make decisions slowly and involve multiple levels of decision marking this can be challenging given the pace of development in healthtech. They have limited interest in untested innovation or having to patchwork together lots of solutions. Providing a ready to go, safe and tested solution that fixes a current issue, particularly around improving patient flows, reducing DNAs and patient communication is key to getting contracts. It’s key to both get trust from both the management and front line clinicians to get the first NHS contracts. You need to demonstrate value from day 1 and then leverage these case studies to scale.
Chris: If you were building a new HealthTech company today, which area of digital health would you focus on and why?
James: I’d focus on patient led prevention and proactive care, particularly for chronic diseases. We’re still too reactive and Dr focused as a health system, waiting until people are sick before bringing them into hospital. With advances in data, remote monitoring, and AI, we now have the tools to predict risk and target interventions before disease develops. That’s not just better for patients, it’s also the only way to make national healthcare sustainable in the long term.
James’s journey shows that transforming healthcare requires more than great ideas, it takes clinical insight, technical expertise and the ability to turn innovation into practical, scalable solutions. His experiences offer valuable lessons for founders, investors and anyone looking to make a real impact in healthtech.
